COMP <GO>
SUPN vs ZLAB // OPERATING MARGIN
Supernus Pharmaceuticals Inc. (NASDAQ) VS. Zai Lab Limited (NASDAQ) • 15-METRIC TALLY: SUPN 8
— ZLAB 2
▲ OPERATING MARGIN LEADER: SUPN
LAST: $41.92 (+0.19%) • MKT CAP: $2.43B
operating-margins
-8.70%
LAST: $22.07 (-1.30%) • MKT CAP: $2.51B
operating-margins
-50.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. ZLAB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | ZLAB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 58.30% | +31.30 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | -35.00% | +30.50 | SUPN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | -6.33% | +8.22 | SUPN | /fcf-yield <GO> |
| Operating Margin ACTIVE | -8.70% | -50.20% | +41.50 | SUPN | /operating-margins <GO> |
| Net Profit Margin | -5.40% | -38.40% | +33.00 | SUPN | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 15.00% | -6.40 | ZLAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 0.52 | +4.32 | SUPN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | SUPN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 42.0 | +8.50 | SUPN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $2.51B | -$78.2M | ZLAB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | ZLAB REV | SUPN GROSS % | ZLAB GROSS % | SUPN FCF | ZLAB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $457.2M | 89.6% | 58.3% | $46.0M | -$158.9M |
| FY 2024 | $661.8M | $397.6M | 88.2% | 63.0% | $171.2M | -$220.5M |
| FY 2023 | $607.5M | $266.7M | — | — | $83.7M | -$198.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
ZLAB // BETA —